Exercise for Prostate Cancer Patients (EXCAP)

This study is ongoing, but not recruiting participants.
United States Department of Defense
Information provided by (Responsible Party):
Karen Mustian, University of Rochester
ClinicalTrials.gov Identifier:
First received: December 29, 2008
Last updated: November 4, 2015
Last verified: November 2015
The purpose of this study is to gain a better understanding of the mechanisms responsible for cancer-related fatigue.

Condition Intervention
Behavioral: Exercise

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Supportive Care
Official Title: The Influence of Home-based Aerobic and Resistance Exercise on Cancer-Related Fatigue, Strength, and Muscle Mass in Prostate Patients.

Resource links provided by NLM:

Further study details as provided by University of Rochester:

Primary Outcome Measures:
  • Cancer-related fatigue [ Time Frame: 4.5 Months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To provide preliminary data on influence of home-based aerobic and resistance exercise on strength, skeletal muscle mass, inflammatory response, QOL and it's relationship to CRF [ Time Frame: 4.5 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 122
Study Start Date: December 2007
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Treatment Arm 1
Usual Care: Standard care monitoring
Experimental: Treatment arm 2
Home-based Exercise: Progressive walking and resistance exercise treatment.
Behavioral: Exercise
Progressive walking and resistance exercise treatment

  Show Detailed Description


Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have a primary diagnosis of prostate cancer
  • Have a KPS of 60 or greater.
  • Be receiving any form of treatment for their prostate cancer or have received some form of treatment (e.g. surgery, chemotherapy, radiation therapy, hormone therapy) in the last 10 years
  • Have approval of physician and be able to read English.
  • Be 21 years of age or older and give informed consent

Exclusion Criteria:

  • Have bone metastases that preclude participation due to symptoms such as pain or location of the bone metastasis.
  • Have physical limitations that contraindicate participation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00815672

United States, New York
James P. Wilmot Cancer Center, University of Rochester
Rochester, New York, United States, 14642
Sponsors and Collaborators
University of Rochester
United States Department of Defense
Principal Investigator: Karen Mustian, Ph.D. James P. Wilmot Cancer Center, University of Rochester
  More Information

Responsible Party: Karen Mustian, Associate Professor, University of Rochester
ClinicalTrials.gov Identifier: NCT00815672     History of Changes
Other Study ID Numbers: 1703DOD 
Study First Received: December 29, 2008
Last Updated: November 4, 2015
Health Authority: United States: Federal Government

Keywords provided by University of Rochester:
Prostate cancer

Additional relevant MeSH terms:
Signs and Symptoms

ClinicalTrials.gov processed this record on April 27, 2016